Breaking News Instant updates and real-time market news.

XLRN

Acceleron

$42.11

-0.83 (-1.93%)

09:05
01/08/18
01/08
09:05
01/08/18
09:05

Acceleron announces 'positive' preliminary results from Part 1 of ACE-083 trial

Acceleron Pharma announced positive preliminary results for the first two cohorts in Part 1 of the Phase 2 clinical trial with ACE-083 in patients with facioscapulohumeral dystrophy, a rare genetic muscle disorder that results in progressive focal muscle loss and weakness. The company plans to initiate Part 2 of the ACE-083 FSHD Phase 2 trial during 2Q18. Part 1 of the Phase 2 trial is an open-label, dose-escalation study of ACE-083 designed to evaluate safety as well as changes in total muscle volume in up to 36 patients with FSHD. Preliminary results include data from 23 patients evaluable for magnetic resonance imaging among two different cohorts. Each patient received ACE-083 as a unilateral intramuscular injection once every three weeks for 12 weeks. Total muscle volume changes were measured by MRI relative to baseline at 3 weeks after the last injection of ACE-083. Based on overlap in dosing on a milligram per gram muscle analysis, dose cohorts were pooled for the analyses of each muscle. The tibialis anterior, which is located in the lower leg, is the main muscle responsible for ankle dorsiflexion, or the ability to lift the front of the foot when taking a step. Over 70% of FSHD patients experience tibialis anterior weakness over the course of their disease, which can lead to general decreased mobility and an increased frequency of falling. The TA cohorts generated a mean total muscle volume increase of 12.6%. The TA cohorts produced a mean decrease or improvement in muscle fat fraction of 5.3%. The biceps brachii, which is located in the upper arm, is a major muscle responsible for elbow flexion, or the ability to lift the lower arm. A majority of FSHD patients experience biceps brachii weakness early in their disease, which leads to the inability to lift objects or perform other important daily activities without assistance. The BB cohorts generated a mean total muscle volume increase of 13.2%. The BB cohorts produced a mean decrease or improvement in muscle fat fraction of 0.6%. In the BB cohorts, the majority of patients had less intramuscular fat at baseline relative to the patients in the TA cohorts. Patients with higher fat fraction in the BB cohorts at baseline demonstrated larger decreases in fat fraction with treatment. Strength and function tests are being explored in Part 1 to assist with the design of the randomized, double-blind, placebo-controlled Part 2 of the study. Given the lack of placebo control and small sample size of patients in Part 1, no conclusions can be made on the strength and function assessments at this time. Effects of ACE-083 on strength and function versus a placebo-control will be evaluated in Part 2 of the study. There were no serious adverse events reported. The most common adverse events were injection site related and grades 1-2. One patient experienced a related grade 3 non-serious adverse event of lower leg intramuscular swelling. This patient fully recovered and was discontinued from the study.

  • 08

    Jan

XLRN Acceleron
$42.11

-0.83 (-1.93%)

09/20/17
JEFF
09/20/17
NO CHANGE
Target $160
JEFF
Buy
Jefferies sees Celgene shares 'grinding' higher into 2018
Commentary from partner Acceleron Pharma's (XLRN) R&D day indicates Celgene (CELG) will announce lots of data in 2018, Jefferies analyst Michael Yee tells investors in a research note. He sees Celgene shares "grinding higher" over the next few months and into 2018 ahead of three major Phase III datasets: GED-301 in Crohn's, Ozanimod in ulcerative colitis and partner Acceleron's luspatercept in beta-thalassemia. The analyst keeps a Buy rating on Celgene with a $160 price target.
10/12/17
HCWC
10/12/17
INITIATION
Target $57
HCWC
Buy
Acceleron initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White started Acceleron Pharma with a Buy rating and $57 price target. The analyst thinks luspatercept could be brought to the market by late 2019, and will achieve blockbuster sales by 2026.
11/07/17
HCWC
11/07/17
NO CHANGE
Target $62
HCWC
Buy
Acceleron price target raised to $62 from $57 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Acceleron Pharma to $62 following the company's Q3 results and pipeline update citing an increase in cash levels. Acceleron indicated that it will have enough cash after its September offering to fund operations into 2021, White points out. He keeps an Outperform rating on the shares.
11/14/17
FBCO
11/14/17
NO CHANGE
Target $51
FBCO
Outperform
Acceleron price target raised to $51 from $35 at Credit Suisse
Credit Suisse analyst Alethia Young raised her price target for Acceleron to $51 from $35 due to increased confidence in the commercial market opportunity for Phase 3 asset luspatercept. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$273.68

0.42 (0.15%)

12:05
05/22/18
05/22
12:05
05/22/18
12:05
Hot Stocks
Leon Cooperman thinks market is fairly valued »

Cooperman is speaking on…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$273.68

0.42 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NE

Noble Corp.

$6.31

0.295 (4.91%)

12:05
05/22/18
05/22
12:05
05/22/18
12:05
Options
Noble Corp. call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$273.67

0.41 (0.15%)

12:03
05/22/18
05/22
12:03
05/22/18
12:03
Technical Analysis
Technical Take: SPDR S&P 500 ETF in middle of range at mid-session »

The SPDR S&P 500 ETF…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$273.67

0.41 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$88.39

1.1 (1.26%)

, ATVI

Activision Blizzard

$71.45

(0.00%)

12:02
05/22/18
05/22
12:02
05/22/18
12:02
Hot Stocks
Hasbro, Activision Blizzard sign licensing agreement for Overwatch »

Hasbro (HAS) announced…

HAS

Hasbro

$88.39

1.1 (1.26%)

ATVI

Activision Blizzard

$71.45

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCP

J.C. Penney

$2.36

-0.145 (-5.79%)

, LOW

Lowe's

$86.43

-0.94 (-1.08%)

12:01
05/22/18
05/22
12:01
05/22/18
12:01
General news
On The Fly: Top stock stories at midday »

Stocks opened in positive…

JCP

J.C. Penney

$2.36

-0.145 (-5.79%)

LOW

Lowe's

$86.43

-0.94 (-1.08%)

KSS

Kohl's

$60.56

-4.91 (-7.50%)

MU

Micron

$59.33

3.85 (6.94%)

INTC

Intel

$54.45

0.13 (0.24%)

PLAB

Photronics

$9.05

0.6 (7.10%)

GSM

Ferroglobe

$11.87

0.52 (4.58%)

PSTG

Pure Storage

$21.75

-1.85 (-7.84%)

AZO

AutoZone

$611.74

-53.94 (-8.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 30

    May

  • 07

    Jun

  • 12

    Jun

  • 10

    Jul

NVTA

Invitae

$7.41

0.1697 (2.34%)

11:55
05/22/18
05/22
11:55
05/22/18
11:55
Hot Stocks
Breaking Hot Stocks news story on Invitae »

ARK Investment reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

AWK

American Water

$80.80

0.3 (0.37%)

11:51
05/22/18
05/22
11:51
05/22/18
11:51
Hot Stocks
Illinois American Water invests approx. $430,000 in Ransom drinking water system »

Illinois American Water…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$71.78

0.4 (0.56%)

11:50
05/22/18
05/22
11:50
05/22/18
11:50
Options
Notable spreads in Nike »

Notable spreads in Nike.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

XLE

Energy Select Sector SPDR

$79.27

0.4 (0.51%)

11:46
05/22/18
05/22
11:46
05/22/18
11:46
Technical Analysis
Technical Take: Energy Select Sector SPDR hits new 52-week high »

At time of writing the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$85.71

-3.64 (-4.07%)

11:45
05/22/18
05/22
11:45
05/22/18
11:45
Recommendations
BioMarin analyst commentary  »

BioMarin 'raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 25

    May

  • 12

    Sep

DO

Diamond Offshore

$20.60

0.71 (3.57%)

11:45
05/22/18
05/22
11:45
05/22/18
11:45
Options
Diamond Offshore call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALB

Albemarle

$104.25

0.17 (0.16%)

11:41
05/22/18
05/22
11:41
05/22/18
11:41
Conference/Events
Albemarle management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 30

    May

  • 04

    Jun

  • 05

    Jun

GIS

General Mills

$42.00

0.23 (0.55%)

11:40
05/22/18
05/22
11:40
05/22/18
11:40
Conference/Events
General Mills management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

11:38
05/22/18
05/22
11:38
05/22/18
11:38
General news
4-Week Bill Auction Total Amount data reported »

4-Week Bill Auction Total…

11:38
05/22/18
05/22
11:38
05/22/18
11:38
General news
52-Week Bill Auction Bid/Cover data reported »

52-Week Bill Auction…

11:38
05/22/18
05/22
11:38
05/22/18
11:38
General news
52-Week Bill Auction Total Amount data reported »

52-Week Bill Auction…

MYND

MYnd Analytics

$2.66

-0.5 (-15.82%)

11:33
05/22/18
05/22
11:33
05/22/18
11:33
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZO

AutoZone

$620.18

-45.5 (-6.84%)

11:32
05/22/18
05/22
11:32
05/22/18
11:32
Technical Analysis
Technical Take: AutoZone back near lows of the day »

After a brief bounce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

TJX

TJX

$87.50

2.84 (3.35%)

11:30
05/22/18
05/22
11:30
05/22/18
11:30
Earnings
TJX sees Q2 revenue approx. $9B, consensus $8.47B »

Expects wage increases to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

RCII

Rent-A-Center

$10.07

-0.14 (-1.37%)

11:30
05/22/18
05/22
11:30
05/22/18
11:30
Options
Notable ratio spread in Rent A Center »

Notable ratio spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TJX

TJX

$86.77

2.11 (2.49%)

11:28
05/22/18
05/22
11:28
05/22/18
11:28
Earnings
TJX sees FY19 revenue $37.7B-$37.9B, consensus $37.87B »

Expects pretax profit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

TGT

Target

$76.39

-0.47 (-0.61%)

, AMZN

Amazon.com

$1,580.04

-5.51 (-0.35%)

11:27
05/22/18
05/22
11:27
05/22/18
11:27
Earnings
On The Fly: What to watch in Target's earnings report »

Target (TGT) is scheduled…

TGT

Target

$76.39

-0.47 (-0.61%)

AMZN

Amazon.com

$1,580.04

-5.51 (-0.35%)

WMT

Walmart

$84.33

-0.17 (-0.20%)

SHLD

Sears

$3.35

-0.29 (-7.97%)

JCP

J.C. Penney

$2.41

-0.1 (-3.99%)

KSS

Kohl's

$61.15

-4.32 (-6.60%)

W

Wayfair

$84.92

-0.6 (-0.70%)

TSLA

Tesla

$277.25

-7.24 (-2.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 23

    May

  • 30

    May

  • 01

    Jun

  • 04

    Jun

  • 19

    Jun

11:25
05/22/18
05/22
11:25
05/22/18
11:25
Conference/Events
RBC commodity strategist to hold a luncheon meeting »

Group Luncheon Meeting,…

ONCE

Spark Therapeutics

$74.00

0.97 (1.33%)

, BMRN

BioMarin

$85.77

-3.58 (-4.01%)

11:21
05/22/18
05/22
11:21
05/22/18
11:21
Recommendations
Spark Therapeutics, BioMarin analyst commentary  »

Spark Therapeutics should…

ONCE

Spark Therapeutics

$74.00

0.97 (1.33%)

BMRN

BioMarin

$85.77

-3.58 (-4.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 25

    May

  • 10

    Sep

  • 12

    Sep

ADSK

Autodesk

$138.56

1.05 (0.76%)

11:20
05/22/18
05/22
11:20
05/22/18
11:20
Options
Autodesk calls active ahead of earnings »

Autodesk calls active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 14

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.